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Genetically modiﬁed (GM) crops have been developed and commercialized that utilize double stranded
RNAs (dsRNA) to suppress a target gene(s), producing virus resistance, nutritional and quality traits. MON
87411 is a GM maize variety that leverages dsRNAs to selectively control corn rootworm through pro-
duction of a 240 base pair (bp) dsRNA fragment targeting for suppression the western corn rootworm
(Diabrotica virgifera virgifera) Snf7 gene (DvSnf7). A bioinformatics assessment found that endogenous
corn small RNAs matched ~450 to 2300 unique RNA transcripts that likely code for proteins in rat, mouse,
and human, demonstrating safe dsRNA consumption by mammals. Mice were administered DvSnf7 RNA
(968 nucleotides, including the 240 bp DvSnf7 dsRNA) at 1, 10, or 100 mg/kg by oral gavage in a 28-day
repeat dose toxicity study. No treatment-related effects were observed in body weights, food con-
sumption, clinical observations, clinical chemistry, hematology, gross pathology, or histopathology
endpoints. Therefore, the No Observed Adverse Effect Level (NOAEL) for DvSnf7 RNA was 100 mg/kg, the
highest dose tested. These results demonstrate that dsRNA for insect control does not produce adverse
health effects in mammals at oral doses millions to billions of times higher than anticipated human
exposures and therefore poses negligible risk to mammals.
© 2016 Monsanto Company. Published by Elsevier Inc. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Ribonucleic Acids (RNA) are ubiquitous bio-molecules funda-
mental to life and, therefore, are abundant in food and feed that has
an extensive history of safe consumption. This safe consumption
includes RNA molecules of varying types ranging from single
stranded RNA, such as messenger RNA (18 to >10,000 nucleotides
for the SAMDC and titin transcripts, respectively), to more complex
RNA structures such as transfer RNAs (typically 76e90 nucleotides)
and ribosomal RNAs (approximately 1500 and 1800 nucleotides for
16S and 18S rRNAs, respectively). Long double stranded RNA
(dsRNA) precursors (e.g. 200e400 base pairs) and small RNAs (e.g.
21e25 base pairs (Carthew and Sontheimer, 2009; Llave et al.,
2002)) are involved in RNA interference (RNAi), a natural mecha-
nism that modulates endogenous gene expression and is foundanded RNA; GM, genetically
RNA; RNA, ribonucleic acid;
etrick).
Elsevier Inc. This is an open acceswidely across plants, animals, and fungi. As a naturally occurring,
ubiquitous process in eukaryotes, RNAi and dsRNA molecules that
modulate endogenous gene expression are present in plants and
animals that have a substantial history of safe consumption. This
safe consumption is remarkable since commonly consumed foods
such as maize, soybean, rice, lettuce, and tomatoes contain both
short (e.g. small interfering RNAs (siRNAs) and micro RNAs) and
long dsRNAs encoding short RNAs with perfect sequence identity to
human and mammalian genes (Ivashuta et al., 2009; Jensen et al.,
2013).
Throughout the crop domestication and plant breeding pro-
cesses, desirable crop phenotypes that are now known to be
mediated through RNAi have been selected (Della Vedova et al.,
2005; Tuteja et al., 2004). The RNAi mechanism has also been
leveraged in the development of GM crops with quality traits and
with virus resistance (Frizzi and Huang, 2010; Kamthan et al., 2015;
Parrott et al., 2010) and has been recently developed as a highly
selective tool for insect control (Bachman et al., 2013; Baum et al.,
2007; Mao et al., 2007). In light of a long history of safe RNA con-
sumption discussed above, the fact that RNAi does not represent a
novel mechanism for developing crop traits, and the broaders article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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to conclude that applications of dsRNA in agricultural biotech-
nology are safe (Petrick et al., 2013, 2015).
The safety of ingested nucleic acids, including RNA, is well un-
derstood from several perspectives, including the simple fact that
humans consume signiﬁcant amounts of RNA with every meal of
plant and animal derived ingredients (Jonas et al., 2001). This safety
is driven not by the sequence of the ingested RNA (recall that
humans safely consume RNA with sequence matches to their
genome and transcriptome as noted above) but rather, by a highly
effective set of biological barriers that greatly limit the potential for
biologically meaningful exposures to ingested RNAs (Petrick et al.,
2013, 2015). Formidable barriers against exogenous RNAs are
evident from investigative research into RNA therapeutics
(reviewed by (Juliano et al., 2009; Juliano, 2016; O'Neill et al., 2011;
Petrick et al., 2013)) and these barriers have limited the potential
for systemic RNA therapeutics. More notably, these barriers have
been the source of insurmountable challenges to the development
of oral RNA-based therapeutics to date. These barriers necessitate
the use of direct injections, chemical modiﬁcations/stabilization,
and specialized delivery formulations for systemic drugs (Behlke,
2006) and ensure very low oral bioavailability of oligonucleotide
drugs (i.e. <1%) after oral administration (Nicklin et al., 1998;
Petrick et al., 2013).
The efﬁcacy of biological barriers against ingested dietary RNAs
in vivo is demonstrated by feeding studies with plant-derived
materials/foods and/or dsRNAs (Dickinson et al., 2013; Petrick
et al., 2015; Snow et al., 2013; Witwer and Hirschi, 2014; Witwer
et al., 2013). Further evidence of the impact of these barriers is
also provided by the noted difﬁculties in achieving oral delivery of
nucleic acid drugs for diseases of the intestinal tract (e.g. local
rather than systemic delivery) (Knipe et al., 2016). Barriers to
ingested dsRNAs include pH extremes and nucleases in the
gastrointestinal tract and in blood (Juliano et al., 2009; O'Neill et al.,
2011; Petrick et al., 2013). However, even when RNA targeting a rat
gene is injected intravenously (i.v.) into rats, bypassing several of
the aforementioned gastrointestinal and membrane barriers, at
doses up to 200 mg/kg body weight it does not produce adverse
effects (Thompson et al., 2012). This provides strong evidence for
the impact of exogenous dsRNA barriers beyond the gastrointes-
tinal tract. For example, it has been shown that exogenous systemic
dsRNAs are extensively degraded in the blood within minutes
following i.v. dosing (evenwhen chemically stabilized (Christensen
et al., 2013);) and that these dsRNAs undergo rapid renal elimina-
tion (Molitoris et al., 2009; Vaishnaw et al., 2010).
Cellular transit of highly polar macromolecules such as dsRNAs
is limited by a series of membrane barriers that separate the in-
testinal lumen from the vasculature, and the vasculature from any
putative systemic target tissues (e.g. epithelial and endothelial
cellular membranes) (Reviewed by (Juliano et al., 2009; O'Neill
et al., 2011; Petrick et al., 2013). The possibility that orally inges-
ted dsRNA could have a systemic effect is highly unlikely when one
considers the ingested dsRNA has to: 1) be absorbed in a func-
tionally intact form from the GI tract and in quantities suitable for
mediating RNAi despite being subjected to a series of cellular
membrane barriers that limit the transit of polar molecules and a
hydrolytic environment that typically degrades nucleic acids, 2)
avoid degradation by blood nucleases, 3) avoid renal elimination, 4)
pass through the cellular membrane of the target cell, and 5) avoid
sequestration in endosomes (since polar RNA molecules do not
have direct cytoplasmic access, but are subject to endocytic vesicle
uptake). Sequestration in endosomes is important to RNA fate
because RNAs may be shunted to lysosomes (for degradation) and/
or may undergo subsequent degradation by intracellular nucleases
(Forbes and Peppas, 2012; Gilmore et al., 2004; Juliano, 2016). Thesequestration of RNAs in endosomes, where the contents remain
outside of the cytoplasmic space, represents a signiﬁcant barrier to
putative activity by any systemically absorbed exogenous dsRNAs,
as only 1e2% of dsRNAs entering the cell are able to escape from
this compartment (Gilleron et al., 2013). Theweight of the scientiﬁc
evidence, including in vivo testing, therefore supports the conclu-
sion of rapid metabolism and clearance and low intracellular ex-
posures resulting from exogenous dsRNA exposures. This weight of
the evidence is especially strong for dsRNAs ingested from the diet
which have a limited toxicity potential, due to additional barriers
afforded by the gastrointestinal tract (Knipe et al., 2016) and is
therefore particularly applicable to dsRNAs composed of naturally
occurring nucleotides that would be expressed in GM crops (i.e.,
unformulated and unstabilized dsRNAs).
MON 87411 expresses the Bacillus thuringiensis (Bt)-derived
toxin Cry3Bb1 and an RNA molecule, DvSnf7 RNA, to protect maize
from corn rootworm damage. The DvSnf7 RNA expressed in MON
87411 is composed of a 968 nucleotide sequence containing a corn
rootworm-active 240 base pair double stranded RNA (dsRNA)
component plus the addition of a poly A tail (Urquhart et al., 2015).
DvSnf7 RNA confers selective control (i.e., activity is limited to a
subset of the Galerucinae subfamily) against corn rootworm
through suppression of the insect Snf7 gene (Bachman et al., 2013).
Therefore, although DvSnf7 is orally active against Diabrotica vir-
gifera virgifera, Bachman and colleagues demonstrate that it is toxic
to only a narrow spectrum of insects that are both closely related
and susceptible to ingested RNA. Therefore, since a number of
species that are closely related to Diabrotica but fall outside the
Galerucinae subfamily of beetles are not susceptible to DvSnf7 RNA,
based on both sequence divergence and biological barriers, activity
or toxicity in more distantly related mammalian species would not
be anticipated.
As an additional assurance of the absence of a hazard to mam-
mals, the potential for toxicity of the 968 nucleotide rootworm-
active RNA, DvSnf7, was evaluated in a 28-day repeat dose oral
gavage toxicology study inmice at doses of 1, 10, or 100mg/kg body
weight. Following 28 days of consecutive treatment, there was no
toxicity observed in this study and the No Observed Adverse Effect
Level (NOAEL) of DvSnf7 RNA was therefore considered to be
100 mg/kg, the highest dose tested. The results of this study and
exceedingly large margins of exposure relative to anticipated hu-
man exposures described in this paper demonstrate the safety of
DvSnf7 RNA, a rootworm-active RNA expressed in MON 87411 and
illustrate the lack of potential hazard or risk to humans or animals
from dietary exposures to this RNA.
2. Materials and methods
2.1. Bioinformatics assessment
Eight total RNA isolations were conducted from conventional,
non-transgenic maize, LH244: three frommaize grain 25 days after
pollination (DAP), two from maize grain 32 DAP, and three from
maize grain 39 DAP. Small RNAs from these individual maize grain
total RNA samples were isolated after separation on a poly-
acrylamide gel, followed by sequential ligation of cloning adaptors
to these extracts (as described by Llave et al., 2002). This material
was reverse transcribed and the cDNA libraries generated in this
process were sent to 454 Life Sciences (Branford, CT) for deep
sequencing via pyrosequencing. Computer algorithms written in
the Perl programming language (Perl scripts) were used to identify
small RNA inserts within the raw sequence data through identiﬁ-
cation and removal of sequences representing the cloning adaptors.
The sequences from the eight maize grain sequencing libraries
were combined into a single library. After removal of duplicate
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unique sequences of 21e26 nucleotides in length.
All endogenous maize small RNAs that have 100% sequence
identity (21 out of 21 nucleotides or greater) to human, rat, or
mouse transcripts were evaluated using the STELLAR algorithm
(Kehr et al., 2011). Similarly, STELLAR was used to identify matches
between DvSnf7 RNA and human, mouse, and rat transcripts. The
queried human transcriptome contained 98,650 transcript se-
quences (Homo_sapiens_transcript.fasta; dated March 4, 2014).
The queried rat transcriptome contained 116,900 transcript se-
quences (Rattus_norvegicus_transcript.fasta; dated March 9, 2014).
The queried mouse transcriptome contained 250,623 transcript
sequences (Mus_musculus_transcript.fasta; dated March 9, 2014).
Initial alignment data between endogenous maize small RNAs
and human, mouse, and rat transcripts only were ﬁltered to remove
database sequences that are unlikely to be protein coding mRNAs.
This is because protein codingmRNAs represent putative targets for
RNAi-mediated gene suppression. The following types of sequences
were removed frommaize small RNA alignments tomammals only:
ribosomal sequences, small nuclear RNAs, and sequences encoding
predicted genes and pseudogenes, and non-coding RNAs using the
following case-insensitive ﬁlter phrases, “ribosom, small nuclear,
predicted, pseudo, and non-coding”. The resulting transcripts were
therefore considered to be likely protein coding transcripts.
2.2. Test materials
The 968 nucleotide DvSnf7 RNA was synthesized at Monsanto
via in vitro transcription using an E. coli T7 polymerase and was
shown to be equivalent to that produced in MON 87411 as
described by Urquhart and colleagues (Urquhart et al., 2015). The
test material was pooled from ~40 independent 20 ml in vitro
reverse transcription reactions. Following transcription the RNA
was heated to ~70 C, and allowed to cool at room temperature to
anneal the RNA inverted repeats and form hairpin loops. DNase
treatment was used to remove any remaining plasmid DNA and
puriﬁed using phenol:chloroform. The pellet was resuspended in
UltraPure Water (Life Technologies, Grand Island, NY), quantiﬁed
using a NanoDrop 8000 spectrophotometer, and stored at 80 C.
The RNA negative control used in the study was torula yeast RNA
(Sigma Aldrich #R6625) formulated in UltraPureWater. The vehicle
control was UltraPure Water obtained from Invitrogen.
The concentration, homogeneity, and 28 day frozen storage
stability/8 h room temperature stability of the test substance were
analytically conﬁrmed by Monsanto Company under GLP condi-
tions using a NanoDrop 8000 spectrophotometer (Thermo Scien-
tiﬁc, Wilmington, DE; data not shown) and the intactness of the
analyzed RNA was conﬁrmed by visualization after separation via
formaldehyde agarose gel electrophoresis.
DvSnf7 RNA Sequence: 50 ACA CGC TGA ACC GTC TTC GAT ACC
AAG CGG GAG CTC GAC GTC CCT CAG CAG TCG CTG TGC GAT ACC
ATC CAT GAT ATC GTG AAC ATC ATC TAC ATT CAA ATT CTT ATG AGC
TTT CTT AAG GGC ATC TGC AGC ATT TTT CAT AGA ATC TAA TAC AGC
AGT ATT TGT GCT AGC TCC TTC GAG GGC TTC CCT CTG CAT TTC AAT
AGT TGT AAG GGT TCC ATC TAT TTG TAG TTG GGT CTT TTC CAA TCG
TTT CTT CTT TTT GAG GGC TTG GAG TGC AAC TCT TTT ATT TTT CGA
CGC ATT TTT CTT TGC AAG TAC TGC GAT CGC GTT AAC GCT TTA TCA
CGA TAC CTT CTA CCA CAT ATC ACT AAC AAC ATC AAC ACT CAT CAC
TCT CGA CGA CAT CCA CTC GAT CAC TAC TCT CAC ACG ACC GAT TAA
CTC CTC ATC CAC GCG GCC GCC TGC AGG AGC GCA AAG AAA AAT
GCG TCG AAA AAT AAA AGA GTT GCA CTC CAA GCC CTC AAA AAG
AAG AAA CGA TTG GAA AAG ACC CAA CTA CAA ATA GAT GGA ACC
CTT ACA ACT ATT GAA ATG CAG AGG GAA GCC CTC GAA GGA GCT
AGC ACA AAT ACT GCT GTA TTA GAT TCT ATG AAA AAT GCT GCA
GAT GCC CTT AAG AAA GCT CAT AAG AAT TTG AAT GTA GAT GATGTT CAC GAT ATC ATG GAT TAG ATC GCC AGC GGT ACT CGC TGA
GGC CTAGCT TTC GTT CGTATC ATC GGT TTC GAC AAC GTT CGT CAA
GTT CAA TGC ATC AGT TTC ATT GCG CAC ACA CCAGAATCC TAC TGA
GTT TGA GTA TTA TGG CAT TGG GAA AAC TGT TTT TCT TGT ACC ATT
TGT TGT GCT TGT AAT TTA CTG TGT TTT TTA TTC GGT TTT CGC TAT
CGA ACT GTG AAA TGG AAA TGG ATG GAG AAG AGT TAA TGA ATG
ATA TGG TCC TTT TGT TCA TTC TCA AA 30.2.3. Toxicology study
CD-1 mice from Charles River Laboratories Inc. (Portage, MI)
were utilized to conduct a 28-day repeat oral dose (gavage) toxicity
study, with a design adapted from OECD Test Guideline 407.
Although the rat is the preferred rodent species for this test
guideline, mice were selected as the test species for this study due
to test substance limitations. This study was conducted at a testing
facility (Xenometrics; Stillwell, KS) that is fully accredited by the
Association for Assessment and Accreditation of Laboratory Animal
Care International (AAALAC) and is registered with the United
States Department of Agriculture (USDA). This studywas conducted
according to Good Laboratory Practices (GLP) of the United States
Environmental Protection Agency.
Upon receipt, two sets of 50 male and 50 female CD-1 mice
weighing 23e36 g were acclimated at least 1 week prior to initia-
tion of pre-study activities and two weeks prior to initiation of
dosing. Animal rooms were maintained at a relative humidity of
30e70%, room temperature of 18e26 C, and on a 12-h light/dark
cycle. Room air was exchanged a minimum daily average of 14
times/h. Animals were individually housed in wire-bottomed
stainless steel cages with a Cozee Pad® cage ﬂoor insert (Lomir
Biomedical, Inc, Malone, NY) andwere provided ad libitum access to
tap water throughout the study and ad libitum access to feed
(Purina Certiﬁed Rodent Lab Diet #5002 in meal form; Purina Mills
Inc., St. Louis, MO) except when they were fasted prior to necropsy.
Animals were identiﬁed via a coded number transmitted by a
subcutaneously implanted transponder (IPTT 300; BioMedic Data
Systems, Inc., Seaford, DE).
Five groups of 10 male and 10 female CD-1 mice were admin-
istered DvSnf7 RNA at 1, 10, or 100 mg/kg bw/day, torula yeast RNA
(RNA negative control) at 100 mg/kg bw/day, or vehicle control
once daily by oral gavage for at least 28 consecutive days to evaluate
the potential for systemic toxicity. Dose groups consisted of ten
mice per sex, rather than ﬁve (speciﬁed by OECD Test Guideline
407) to ensure adequate animal numbers were available for he-
matology and clinical chemistry analysis, as both sets of endpoints
are difﬁcult to obtain from individual mice due to limited blood
volume. Dosing formulations were administered via disposable
sterile gavage cannulas at a dose volume of 20 mL/kg based on the
most recently recorded body weight.
Study endpoints consisted of daily clinical observations, daily
mortality and moribundity checks, weekly detailed observations,
weekly body weights (unfasted) and ﬁnal body weights (fasted for
relative organ weight evaluations), weekly food consumption,
serum chemistry, hematology, gross examination at necropsy, or-
gan weights, and microscopic examination of tissues (vehicle
control, RNA negative control, and high dose test groups only) at
the end of the dosing period. The microscopic examination of tis-
sues was conducted by a board-certiﬁed veterinary pathologist and
subjected to peer review by a second board-certiﬁed veterinary
pathologist. Details of parameters evaluated and methods utilized
for data collection are presented in the supplemental section under
supplemental methods.
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Means and standard deviations were calculated for all quanti-
tative data. As applicable, continuous group mean data (e.g., food
consumption, body weights, organ weights, clinical pathology,
pathology data, etc.) for all statistically examined parameters were
evaluated for homogeneity of variance using Bartlett's test
(Snedecor and Cochran, 1998a). For homogenous data, a one-way
analysis of variance (ANOVA) was performed along with a Dun-
nett's Test for parameters showing a signiﬁcant effect by ANOVA
(Dunnett, 1955, 1964; Snedecor and Cochran, 1998b). Study data
were analyzed for a dose-related trend using the Williams Test
(parametric data) (Williams, 1952) or the Shirley Test (non-para-
metric data) (Konietschke and Ludwig, 2012), which were one-
sided tests, except for the top dose (two-sided test). Gross lesions
and histopathology data were examined statistically using a Chi-
Square Test and/or the Fisher's Exact Test (Hollander and Wolfe,
1973). Statistical evaluations were two-tailed unless indicated
otherwise. For the Bartlett's Test, a probability (p) level 0.001 was
considered signiﬁcant. Data from treated groups (and RNA negative
control) were compared to data from the vehicle control group.
Differences between treatment groups with p values  0.05 were
considered statistically signiﬁcant.
Statistical analyses were performed separately for males and
females. For the purpose of data interpretation, statistical signiﬁ-
cance was not automatically considered to imply toxicological
signiﬁcance. Conversely, the absence of a statistically signiﬁcant
comparison was not considered in isolation to imply the lack of a
biologically relevant effect.
3. Results
3.1. Bioinformatics assessment
Bioinformatic analysis using the STELLAR algorithm (Kehr et al.,
2011), revealed a total of 3,540, 16,206, and 9144 exact 21 nucleo-
tide alignments between endogenous maize grain small RNAs and
human, mouse, and rat transcripts, respectively (Table 1). This
initial set of alignment data betweenmaize small RNAs and human,
mouse, and rat transcripts only was ﬁltered to remove database
sequences that are unlikely to be protein coding mRNAs. This
ﬁltering ensures that only protein coding mRNAs, the putative
targets for RNAi-mediated gene suppression, are represented in the
results. The following types of sequences were removed frommaize
small RNA alignments to mammals: ribosomal sequences, small
nuclear RNAs, and sequences encoding predicted genes, pseudo-
genes, and noncoding RNAs. The resulting transcripts alignments
were therefore considered to be likely protein coding transcripts.
Following this ﬁltering, a total of 500 unique alignments to
human transcripts were identiﬁed (representing 447 unique hu-
man mRNA sequences) that aligned with 150 maize small RNAs.
Similarly, after ﬁltering, a total of 14,395 unique alignments to
mouse transcripts were identiﬁed (representing 2326 uniqueTable 1
Alignments of DvSnf7 and endogenous small RNAs from maize to transcripts from h
Sequence
Primary Alignments from Endogenous Maize Small RNAs
Protein Coding RNA Transcript Alignmentsa
Unique Protein Codinga Target RNAs Identiﬁed
Number of Unique Maize Small RNAs with Alignments
DvSnf7 Alignments
a Likely protein coding sequences are the unique small RNA matches that remain a
and pseudogenes, and non-coding RNAs.mouse mRNA sequences) that aligned with 1346 maize small RNAs.
In rat, this post ﬁltering analysis resulted in identiﬁcation of 8017
unique alignments to rat transcripts (representing 705 unique rat
mRNA sequences) that aligned with 960 maize small RNAs. A
STELLAR search for exact 21 nucleotide alignments between DvSnf7
RNA and human, rat, and mouse transcripts using the same tran-
script databases, but without any ﬁltering of the search results,
revealed no alignments.
3.2. Toxicology assessment
3.2.1. Analytical dose conﬁrmations
The concentrations of the DvSnf7 and torula yeast RNA dosing
formulations used in the 28 day oral toxicity study were analyti-
cally conﬁrmed (by spectrophotometry) to be within ±10% of the
nominal dose concentrations (actual range was 104e110% of
nominal, data not shown), thereby conﬁrming the target doses of 1,
10, or 100mg/kg DvSnf7 RNA and 100mg/kg Torula yeast RNA (RNA
negative control). The individual nucleic acid concentrations of the
top, middle, and bottom strata of the dose formulations were
within ±10% of the average concentration of the respective dose
formulations and the total nucleic acid concentrations in the test
and control dosing solutions at study Day 28 were within ±10% of
the concentration at study Day 0, demonstrating the homogeneity
and stability of the test and control substances and their stability
for the duration of the study. Stability of the test substance and RNA
negative control substance was visually conﬁrmed (e.g. demon-
stration of intactness) by formaldehyde gel electrophoresis at all
dose levels and in all strata following thawing/eight hours of room
temperature incubation and following 28 days of frozen storage
at 80 C (data not shown). These data provide conﬁrmation that
intact RNA was being quantiﬁed. Test animals were therefore
delivered homogenous and stable RNA test and control substances
at the intended concentrations and dose levels are reported as
nominal dose levels.
3.2.2. Clinical observations
Clinical observations recorded during the study indicated that
all animals were healthy throughout the duration of dosing. There
were no impacts on mortality, nor any indications of test
substance-related clinical ﬁndings or indications of pain or distress
during daily observations (data not shown).
3.2.3. Body weight and food consumption
There were no treatment-related or statistically signiﬁcant dif-
ferences in the mean body weights of males or females across the
treatment groups when compared to vehicle controls. Observed
weekly body weights were comparable between control and test
groups in bothmale and female mice (Table 2). Fasted bodyweights
were taken prior to necropsy and these terminal body weights
(study day 29) were slightly lower than study day 28, reﬂecting the
impact of fasting (Supplemental Table 1). There was no impact of
treatment on body weights.umans, mice, and rats.
Human Mouse Rat
3540 16,206 9144
500 14,395 8017
447 2326 705
150 1346 960
0 0 0
fter the ﬁltering steps to remove ribosomal RNAs, small nuclear RNAs, predicted
Table 2
Mean body weights.a
Group Gender Body weight (g) ± SD
Day 1 Day 8 Day 15 Day 22 Day 28 Day 29b
Vehicle Control Male 31.8 ± 2.3 31.9 ± 2.5 32.5 ± 2.5 32.9 ± 2.3 32.1 ± 2.2 28.7 ± 1.9
Female 26.4 ± 1.5 26.8 ± 2.1 28.2 ± 2.4 28.2 ± 1.8 27.4 ± 1.9 24.8 ± 1.8
RNA negative control 100 mg/kg/day Male 32.1 ± 1.7 32.0 ± 2.0 32.9 ± 2.0 33.2 ± 1.9 32.6 ± 2.1 29.2 ± 2.1
Female 26.1 ± 1.0 25.2 ± 1.2 27.2 ± 1.6 27.2 ± 1.3 26.5 ± 1.3 24.2 ± 1.2
DvSnf7 RNA 1 mg/kg/day Male 31.7 ± 2.5 31.3 ± 1.9 33.0 ± 2.2 33.2 ± 3.0 33.2 ± 2.6 29.8 ± 1.9
Female 26.1 ± 1.4 26.5 ± 1.6 27.8 ± 1.3 28.7 ± 1.3 27.1 ± 1.6 25.2 ± 1.9
DvSnf7 RNA 10 mg/kg/day Male 31.9 ± 2.4 32.5 ± 1.7 33.8 ± 2.2 33.7 ± 2.0 33.6 ± 2.3 30.2 ± 2.0
Female 26.4 ± 1.9 25.8 ± 1.5 26.9 ± 1.8 27.5 ± 1.5 26.2 ± 2.2 24.1 ± 2.1
DvSnf7 RNA 100 mg/kg/day Male 31.3 ± 1.8 31.4 ± 1.8 32.8 ± 1.9 33.4 ± 1.6 32.8 ± 1.5 29.4 ± 1.6
Female 26.5 ± 1.4 26.0 ± 1.1 27.3 ± 1.2 27.7 ± 1.2 26.6 ± 1.4 24.4 ± 1.2
a No statistically signiﬁcant differences were observed. n ¼ 10 mice per group.
b Day 29 body weights were taken on fasted animals, thus lower weights reﬂect fasting rather than body weight differences due to treatment.
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of both male and female mice (Supplemental Table 2). There were
no treatment-related differences in food consumption.
3.2.4. Clinical chemistry
There were no treatment-related differences in any of theTable 3
Clinical chemistry evaluation.
Parameter Gender Vehicle control RNA negative co
Na (mM) Male 158 ± 2 (n ¼ 8) 156 ± 5 (n ¼ 7)
Female 161 ± 9 (n ¼ 8) 160 ± 7 (n ¼ 10)
K (mM) Male 9.9 ± 0.7 (n ¼ 8) 9.7 ± 0.9 (n ¼ 7)
Female 8.9 ± 0.7 (n ¼ 8) 9.0 ± 0.9 (n ¼ 10
Cl (mM) Male 113 ± 2 (n ¼ 8) 111 ± 2 (n ¼ 7)
Female 117 ± 10 (n ¼ 8) 118 ± 10 (n ¼ 10
Urea Nitrogen (mg/dL) Male 31 ± 6 (n ¼ 8) 32 ± 9 (n ¼ 6)
Female 21 ± 2 (n ¼ 9) 20 ± 3 (n ¼ 10)
Glucose (mg/dL) Male 197 ± 43 (n ¼ 8) 216 ± 53 (n ¼ 7)
Female 186 ± 39 (n ¼ 8) 175 ± 43 (n ¼ 10
Creatinine (mg/dL) Male 0.4 ± 0.0 (n ¼ 8) 0.4 ± 0.0 (n ¼ 7)
Female 0.4 ± 0.0 (n ¼ 8) 0.4 ± 0.0 (n ¼ 10
Uric acid (mg/dL) Male 2.6 ± 0.7 (n ¼ 8) 2.7 ± 0.8 (n ¼ 6)
Female 2.2 ± 1.1 (n ¼ 9) 1.9 ± 0.6 (n ¼ 10
Triglycerides (mg/dL) Male 69 ± 14 (n ¼ 8) 56 ± 11 (n ¼ 6)
Female 61 ± 14 (n ¼ 9) 61 ± 19 (n ¼ 10)
Cholesterol (mg/dL) Male 148 ± 27 (n ¼ 8) 139 ± 17 (n ¼ 6)
Female 94 ± 20 (n ¼ 9) 94 ± 19 (n ¼ 10)
AST (U/L) Male 82 ± 28 (n ¼ 8) 80 ± 31 (n ¼ 6)
Female 104 ± 30 (n ¼ 9) 126 ± 60 (n ¼ 10
ALT (U/L) Male 27 ± 4 (n ¼ 8) 26 ± 7 (n ¼ 7)
Female 26 ± 3 (n ¼ 8) 46 ± 45 (n ¼ 10)
GGT (U/L) Male 0 ± 0a (n ¼ 8) 0 ± 0a (n ¼ 7)
Female 0 ± 0a (n ¼ 8) 0 ± 0a (n ¼ 10)
ALP (U/L) Male 74 ± 13 (n ¼ 8) 76 ± 14 (n ¼ 6)
Female 80 ± 27 (n ¼ 9) 91 ± 40 (n ¼ 10)
Total Bilirubin (m/dL) Male 0.1 ± 0.1 (n ¼ 8) 0.1 ± 0.1 (n ¼ 6)
Female 0.1 ± 0.0 (n ¼ 9) 0.1 ± 0.1 (n ¼ 10
Total Protein (g/dL) Male 5.6 ± 0.3 (n ¼ 8) 5.6 ± 0.2 (n ¼ 6)
Female 5.6 ± 0.2 (n ¼ 9) 5.6 ± 0.3 (n ¼ 10
Albumin (g/dL) Male 3.4 ± 0.2 (n ¼ 8) 3.4 ± 0.2 (n ¼ 6)
Female 3.6 ± 0.1 (n ¼ 9) 3.6 ± 0.2 (n ¼ 10
Phosphorus (mg/dL) Male 9.3 ± 1.5 (n ¼ 8) 8.1 ± 1.5 (n ¼ 7)
Female 9.3 ± 1.4 (n ¼ 8) 8.5 ± 1.1 (n ¼ 10
Calcium (mg/dL) Male 9.9 ± 0.1 (n ¼ 8) 9.3 ± 1.4 (n ¼ 7)
Female 10.2 ± 0.2 (n ¼ 8) 10.1 ± 0.4 (n ¼ 1
Globulin (g/dL) Male 2.2 ± 0.1 (n ¼ 8) 2.2 ± 0.1 (n ¼ 6)
Female 2.0 ± 0.1 (n ¼ 9) 2.1 ± 0.2 (n ¼ 10
Albumin/Globulin ratio Male 1.5 ± 0.1 (n ¼ 8) 1.6 ± 0.1 (n ¼ 6)
Female 1.8 ± 0.1 (n ¼ 9) 1.7 ± 0.1 (n ¼ 10
Statistics: ANOVA þ Dunnett's test (Two-Sided) to compare each test group to the contr
*P  0.05.
a Data not appropriate for statistical analysis.clinical chemistry parameters evaluated for males or females
(Table 3). Sodium levels in the 10 and 100 mg/kg male groups were
slightly higher than in the vehicle control group males. However,
these differences were not considered toxicologically relevant for
the following reasons: there was no dose response (same sodium
value in both groups and yet a 10-fold difference in dose), therewasntrol DvSnf7 RNA
1 mg/kg/day 10 mg/kg/day 100 mg/kg/day
159 ± 3 (n ¼ 10) 161 ± 3* (n ¼ 9) 161 ± 2* (n ¼ 9)
166 ± 6 (n ¼ 9) 166 ± 7 (n ¼ 10) 165 ± 8 (n ¼ 9)
9.6 ± 1.2 (n ¼ 10) 9.6 ± 2.2 (n ¼ 9) 10.0 ± 0.7 (n ¼ 10)
) 9.2 ± 1.0 (n ¼ 9) 9.3 ± 0.5 (n ¼ 10) 9.0 ± 0.7 (n ¼ 9)
111 ± 2 (n ¼ 10) 113 ± 2 (n ¼ 9) 112 ± 2 (n ¼ 10)
) 123 ± 8 (n ¼ 9) 124 ± 9 (n ¼ 10) 124 ± 9 (n ¼ 9)
37 ± 12 (n ¼ 10) 32 ± 9 (n ¼ 10) 31 ± 9 (n ¼ 10)
19 ± 3 (n ¼ 9) 20 ± 3 (n ¼ 10) 20 ± 3 (n ¼ 9)
205 ± 32 (n ¼ 10) 202 ± 31 (n ¼ 8) 230 ± 41 (n ¼ 10)
) 192 ± 29 (n ¼ 9) 182 ± 40 (n ¼ 10) 168 ± 24 (n ¼ 9)
0.4 ± 0.0 (n ¼ 10) 0.4 ± 0.1 (n ¼ 8) 0.4 ± 0.0 (n ¼ 10)
) 0.4 ± 0.1 (n ¼ 9) 0.4 ± 0.0 (n ¼ 10) 0.4 ± 0.0 (n ¼ 9)
2.7 ± 0.5 (n ¼ 10) 2.5 ± 0.5 (n ¼ 10) 2.6 ± 0.4 (n ¼ 10)
) 2.4 ± 0.6 (n ¼ 9) 1.8 ± 0.5 (n ¼ 10) 1.7 ± 0.4 (n ¼ 9)
66 ± 24 (n ¼ 10) 76 ± 20 (n ¼ 10) 66 ± 17 (n ¼ 10)
64 ± 16 (n ¼ 9) 53 ± 15 (n ¼ 10) 63 ± 11 (n ¼ 9)
141 ± 34 (n ¼ 10) 134 ± 33 (n ¼ 10) 136 ± 19 (n ¼ 10)
102 ± 31 (n ¼ 9) 91 ± 19 (n ¼ 10) 81 ± 17 (n ¼ 9)
76 ± 22 (n ¼ 10) 80 ± 27 (n ¼ 10) 72 ± 18 (n ¼ 10)
) 98 ± 27 (n ¼ 9) 101 ± 21 (n ¼ 10) 94 ± 21 (n ¼ 9)
33 ± 19 (n ¼ 10) 28 ± 6 (n ¼ 8) 28 ± 4 (n ¼ 10)
27 ± 5 (n ¼ 9) 32 ± 10 (n ¼ 10) 28 ± 4 (n ¼ 9)
0 ± 0a (n ¼ 10) 0 ± 0a (n ¼ 8) 0 ± 0a (n ¼ 10)
0 ± 0a (n ¼ 9) 0 ± 0a (n ¼ 10) 0 ± 0a (n ¼ 9)
69 ± 16 (n ¼ 10) 67 ± 19 (n ¼ 10) 79 ± 25 (n ¼ 10)
89 ± 30 (n ¼ 9) 90 ± 26 (n ¼ 10) 77 ± 19 (n ¼ 9)
0.2 ± 0.1 (n ¼ 10) 0.1 ± 0.1 (n ¼ 10) 0.2 ± 0.1 (n ¼ 10)
) 0.1 ± 0.0 (n ¼ 9) 0.1 ± 0.0 (n ¼ 10) 0.1 ± 0.0 (n ¼ 9)
5.6 ± 0.3 (n ¼ 10) 5.5 ± 0.3 (n ¼ 10) 5.5 ± 0.2 (n ¼ 10)
) 5.6 ± 0.3 (n ¼ 9) 5.4 ± 0.2 (n ¼ 10) 5.4 ± 0.3 (n ¼ 9)
3.3 ± 0.2 (n ¼ 10) 3.3 ± 0.2 (n ¼ 10) 3.4 ± 0.2 (n ¼ 10)
) 3.5 ± 0.2 (n ¼ 9) 3.4 ± 0.2 (n ¼ 10) 3.4 ± 0.2 (n ¼ 9)
8.7 ± 2.0 (n ¼ 10) 8.9 ± 1.3 (n ¼ 8) 8.9 ± 0.9 (n ¼ 10)
) 9.7 ± 1.1 (n ¼ 9) 9.0 ± 0.6 (n ¼ 10) 8.8 ± 1.2 (n ¼ 9)
9.8 ± 0.3 (n ¼ 10) 9.6 ± 0.3 (n ¼ 8) 9.8 ± 0.2 (n ¼ 10)
0) 10.5 ± 0.3 (n ¼ 9) 9.9 ± 0.6 (n ¼ 10) 10.2 ± 0.5 (n ¼ 9)
2.3 ± 0.1 (n ¼ 10) 2.2 ± 0.2 (n ¼ 10) 2.1 ± 0.1 (n ¼ 10)
) 2.0 ± 0.1 (n ¼ 9) 2.0 ± 0.1 (n ¼ 10) 1.9 ± 0.1 (n ¼ 9)
1.5 ± 0.1 (n ¼ 10) 1.5 ± 0.1 (n ¼ 10) 1.6 ± 0.1 (n ¼ 10)
) 1.7 ± 0.1 (n ¼ 9) 1.7 ± 0.1 (n ¼ 10) 1.8 ± 0.1 (n ¼ 9)
ol group.
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(potassium and chloride) in the males or in female test groups, and
all male test group values were within the normal range as deﬁned
by laboratory historical control data (Sodium level Mean 157mmol/
L, and range: 149e173 mmol/L). Thus, the observed differences
were considered to be the result of normal variation and were not
considered to be toxicologically relevant nor treatment-related.3.2.5. Hematology
There were no test substance related differences in the hema-
tology parameters evaluated in males or females (Table 4).
Observed statistically signiﬁcant differences occurred only in two
differential white blood cell count parameters (e.g. percent cell
counts). Such differences alone are not considered to be toxico-
logically relevant because they provide little information about
what is occurring within the leukogram and therefore absolute
white blood cell counts are the appropriate comparator (Weingand
et al., 1992, 1996). Relative eosinophil counts were statistically
signiﬁcantly higher in the 100 mg/kg/day male group when
compared to the vehicle control group, but absolute eosinophil
counts did not show the same change, and were lower than the
RNA negative control group that did not receive any DvSnf7 RNA.
Although leukocyte differentials can be highly variable in the
normal healthy animal, the percent eosinophil values for high-dose
males fell within the normal range as deﬁned by laboratory his-
torical control data (Mean 5.1%, Range 0e13.6%). Relative monocyte
counts were statistically signiﬁcantly lower in all female groups
when compared to the vehicle control group, but were fairly similar
or slightly higher (e.g. closer to the vehicle control group values)
than those values observed in the RNA negative control group.
Therefore, these differences were likely the result of a compara-
tively high value observed in the vehicle control animals. The
percent monocyte counts for all three groups fell within the normal
range as deﬁned by laboratory historical control data (Mean 1.7%,
Range 0e4.0%). The absence of changes inmonocyte and eosinophilTable 4
Selected Hematology Parameters (Mean ± SD).
Parameter Gender Vehicle control RNA negati
Platelets (103/mm3) Male 1333 ± 225 (n ¼ 8) 1272 ± 157
Female 1315 ± 79 (n ¼ 3) 1189 ± 95 (
White Blood Cells (103/mm3) Male 4.1 ± 1.3 (n ¼ 8) 6.6 ± 2.9 (n
Female 5.0 ± 1.0a (n ¼ 3) 5.4 ± 1.8a (n
Eosinophil (103/mm3)b Male 0.2 ± 0.2 (n ¼ 5) 0.6 ± 0.3 (n
Female nd 0.5 ± 0.1 (n
Eosinophil (%)b Male 2.7 ± 2.8 (n ¼ 10) 6.5 ± 5.5(n
Female 2.0 ± 1.3 (n ¼ 9) 6.0 ± 6.0 (n
Red Blood Cells (106/mm3) Male 10.4 ± 0.5 (n ¼ 8) 10.3 ± 0.7 (
Female 9.9 ± 0.1a (n ¼ 3) 10.0 ± 0.7a
Monocytes (103/mm3)b Male 0.06 ± 0.04 (n ¼ 5) 0.12 ± 0.08
Female nd 0.07 ± 0.05
Monocytes (%)b Male 1.4 ± 1.2 (n ¼ 10) 1.7 ± 0.8 (n
Female 2.6 ± 1.0 (n ¼ 9) 1.1 ± 1.1**
Hemoglobin (g/dL) Male 16.6 ± 0.9 (n ¼ 8) 16.2 ± 1.3 (
Female 16.1 ± 0.3a (n ¼ 3) 15.7 ± 1.3a
Hematocrit (%) Male 53.7 ± 2.3 (n ¼ 8) 53.8 ± 4.2 (
Female 51.5 ± 1.0a (n ¼ 3) 50.9 ± 4.4a
Mean Corpuscular Volume (fL) Male 51.6 ± 1.4 (n ¼ 8) 52.0 ± 1.4 (
Female 52.2 ± 0.7a (n ¼ 3) 51.0 ± 0.8a
Mean Corpuscular Hemoglobin (pg) Male 15.9 ± 0.5 (n ¼ 8) 15.7 ± 0.3 (
Female 16.3 ± 0.3a (n ¼ 3) 15.7 ± 0.3a
MCH Concentration (g/dL) Male 30.9 ± 0.6 (n ¼ 8) 30.2 ± 0.6 (
Female 31.3 ± 0.6a (n ¼ 3) 30.9 ± 0.1a
Statistics: ANOVA þ Dunnett's test (Two-Sided) to compare each test group to the contr
a Data not appropriate for statistical analysis.
b Differential leukocyte counts are provided only for parameters with statistically signabsolute cell counts, values within the normal range for the test
species, and no treatment-related changes in other relevant pa-
rameters (e.g., histopathology of the thymus, spleen, lymph nodes,
bone marrow and liver) indicate that there was no treatment-
related or adverse effects on hematology parameters in this study.3.2.6. Organ weights
There were no treatment-related effects on organ weights in
males or females (Table 5). Lower thyroid weights (about 30%
lower, both absolute and relative to ﬁnal body weight) were noted
in 10 and 100 mg/kg males when compared to vehicle control
(Tables 5 and 6). It is understood that the mouse thyroid is
extremely difﬁcult to trim and because the collection and weighing
process of this small organmay produce artifacts, routine collection
of thyroid weights in mice is not recommended (Sellers et al.,
2007). A clear response to increasing dose was also lacking, as the
thyroid weights were comparable between the 10 and 100 mg/kg
males. There were no apparent differences observed in thyroid
weights of female mice. There were no microscopic changes in the
thyroids of males or females (Table 7). Therefore, the lower thyroid
weights in males only and the absence of any histopathological
correlate indicates that these thyroid weight differences were
spurious and neither treatment-related nor toxicologically
relevant.
Lower ovary weights were noted in the RNA negative control
and all treated groups (both absolute and relative to body weight
when compared to vehicle controls), although this appears to be a
function of abnormally high control ovary weights (Table 5). This
high control weight is evident when average ovary weights in the
control group (0.037 g) are compared to the RNA negative control
group that received no DvSnf7 RNA (0.027 g), a difference of ~25%.
Ovary weights in the test substance treated groups were compa-
rable to the RNA negative control group, thereby indicating that the
observed differences between the test substance and control
groups did not represent a change from the normal range expectedve control DvSnf7 RNA
1 mg/kg/day 10 mg/kg/day 100 mg/kg/day
(n ¼ 8) 1246 ± 295 (n ¼ 9) 1467 ± 351 (n ¼ 10) 1417 ± 317 (n ¼ 9)
n ¼ 2) nd (n ¼ 0) 1054 ± 249 (n ¼ 5) 1214 ± 274 (n ¼ 3)
¼ 8) 4.4 ± 1.6 (n ¼ 9) 6.2 ± 3.2 (n ¼ 10) 5.8 ± 3.4 (n ¼ 9)
¼ 3) 4.7 ± 0.0a (n ¼ 1) 8.7 ± 4.7a (n ¼ 5) 6.9 ± 2.5a (n ¼ 3)
¼ 7) 0.4 ± 0.3 (n ¼ 6) 0.2 ± 0.1 (n ¼ 9) 0.4 ± 0.3 (n ¼ 7)
¼ 3) nd 0.3 ± 0.2 (n ¼ 4) nd
¼ 10) 5.1 ± 5.8 (n ¼ 10) 3.6 ± 2.4 (n ¼ 10) 7.7 ± 6.9* (n ¼ 9)
¼ 7) 2.0 ± 1.9 (n ¼ 8) 1.8 ± 2.2 (n ¼ 9) 2.5 ± 2.1 (n ¼ 9)
n ¼ 8) 10.5 ± 0.8 (n ¼ 9) 10.4 ± 0.4 (n ¼ 10) 10.3 ± 0.9 (n ¼ 9)
(n ¼ 3) 9.3 ± 0.0a (n ¼ 1) 10.1 ± 0.6a (n ¼ 5) 10.5 ± 0.4a (n ¼ 3)
(n ¼ 7) 0.07 ± 0.05 (n ¼ 6) 0.08 ± 0.07 (n ¼ 9) 0.10 ± 0.04 (n ¼ 7)
(n ¼ 3) nd 0.12 ± 0.09(n ¼ 4) nd
¼ 10) 1.5 ± 0.9 (n ¼ 10) 1.5 ± 0.9 (n ¼ 10) 2.0 ± 1.0 (n ¼ 9)
(n ¼ 7) 1.6 ± 1.2** (n ¼ 8) 1.3± 0.5** (n ¼ 9) 1.3 ± 1.0** (n ¼ 9)
n ¼ 8) 16.5 ± 0.8 (n ¼ 9) 16.5 ± 0.7 (n ¼ 10) 16.0 ± 1.0 (n ¼ 9)
(n ¼ 3) 16.5 ± 0.0a (n ¼ 1) 15.9 ± 0.9a (n ¼ 5) 16.7 ± 0.1a (n ¼ 3)
n ¼ 8) 54.5 ± 3.2 (n ¼ 9) 54.5 ± 2.3 (n ¼ 10) 52.8 ± 3.8 (n ¼ 9)
(n ¼ 3) 52.3 ± 0.0a (n ¼ 1) 51.3 ± 2.8a (n ¼ 5) 53.9 ± 1.4a (n ¼ 3)
n ¼ 8) 52.2 ± 2.1 (n ¼ 9) 52.3 ± 1.9 (n ¼ 10) 51.6 ± 2.2 (n ¼ 9)
(n ¼ 3) 56.3 ± 0.0a (n ¼ 1) 50.9 ± 1.3a (n ¼ 5) 51.3 ± 0.9a (n ¼ 3)
n ¼ 8) 15.8 ± 0.7 (n ¼ 9) 15.9 ± 0.8 (n ¼ 10) 15.6 ± 0.5 (n ¼ 9)
(n ¼ 3) 17.8 ± 0.0a (n ¼ 1) 15.8 ± 0.3a (n ¼ 5) 15.9 ± 0.6a (n ¼ 3)
n ¼ 8) 30.3 ± 0.5 (n ¼ 9) 30.4 ± 1.3 (n ¼ 10) 30.3 ± 0.7 (n ¼ 9)
(n ¼ 3) 31.6 ± 0.0a (n ¼ 5) 31.0 ± 0.4a (n ¼ 5) 31.0 ± 0.7a (n ¼ 3)
ol group. *P  0.05. **P  0.01.
iﬁcant differences in the absolute or relative cell counts.
Table 5
Organ weights (Mean ± SD).
Tissue Gender Vehicle control RNA negative control DvSnf7 RNA
1 mg/kg/day 10 mg/kg/day 100 mg/kg/day
Adrenal gland (g)
Male 0.0093 ± 0.0038 (n ¼ 10) 0.0075 ± 0.0016 (n ¼ 10) 0.0096 ± 0.0018 (n ¼ 10) 0.0094 ± 0.0029 (n ¼ 10) 0.0090 ± 0.0034 (n ¼ 10)
Female 0.012 ± 0.003 (n ¼ 10) 0.011 ± 0.003 (n ¼ 10) 0.013 ± 0.003 (n ¼ 10) 0.012 ± 0.004 (n ¼ 10) 0.013 ± 0.003 (n ¼ 10)
Brain (g)
Male 0.48 ± 0.02 (n ¼ 10) 0.48 ± 0.01 (n ¼ 10) 0.48 ± 0.01 (n ¼ 10) 0.47 ± 0.02 (n ¼ 10) 0.47 ± 0.02 (n ¼ 10)
Female 0.47 ± 0.02 (n ¼ 10) 0.47 ± 0.02 (n ¼ 10) 0.48 ± 0.02 (n ¼ 10) 0.48 ± 0.04 (n ¼ 10) 0.49 ± 0.02 (n ¼ 10)
Epididymides (g) Male 0.10 ± 0.01 (n ¼ 10) 0.10 ± 0.02 (n ¼ 10) 0.12 ± 0.02 (n ¼ 10) 0.11 ± 0.02 (n ¼ 10) 0.11 ± 0.02 (n ¼ 10)
Heart (g)
Male 0.16 ± 0.01 (n ¼ 10) 0.17 ± 0.02 (n ¼ 10) 0.16 ± 0.02 (n ¼ 10) 0.17 ± 0.02 (n ¼ 10) 0.17 ± 0.02 (n ¼ 10)
Female 0.14 ± 0.01 (n ¼ 10) 0.14 ± 0.01 (n ¼ 10) 0.13 ± 0.01 (n ¼ 10) 0.14 ± 0.01 (n ¼ 10) 0.14 ± 0.02 (n ¼ 10)
Kidney (g)
Male 0.57 ± 0.07 (n ¼ 10) 0.58 ± 0.06 (n ¼ 10) 0.60 ± 0.06 (n ¼ 10) 0.58 ± 0.06 (n ¼ 10) 0.57 ± 0.03 (n ¼ 10)
Female 0.41 ± 0.04 (n ¼ 10) 0.36 ± 0.08 (n ¼ 10) 0.47 ± 0.26 (n ¼ 10) 0.38 ± 0.05 (n ¼ 10) 0.41 ± 0.03 (n ¼ 10)
Liver (g)
Male 1.25 ± 0.10 (n ¼ 10) 1.28 ± 0.14 (n ¼ 10) 1.40 ± 0.16 (n ¼ 10) 1.35 ± 0.15 (n ¼ 10) 1.39 ± 0.19 (n ¼ 10)
Female 1.06 ± 0.05 (n ¼ 10) 1.13 ± 0.21 (n ¼ 10) 1.09 ± 0.08 (n ¼ 10) 1.16 ± 0.24 (n ¼ 10) 1.16 ± 0.21 (n ¼ 10)
Ovaries (g) Female 0.037 ± 0.010 (n ¼ 10) 0.027 ± 0.004* (n ¼ 10) 0.028 ± 0.010* (n ¼ 10) 0.027 ± 0.007* (n ¼ 10) 0.030 ± 0.005* (n ¼ 10)
Prostate Gland (g) Male 0.39 ± 0.13 (n ¼ 10) 0.32 ± 0.13 (n ¼ 10) 0.39 ± 0.10 (n ¼ 10) 0.31 ± 0.05 (n ¼ 10) 0.30 ± 0.08 (n ¼ 10)
Spleen (g)
Male 0.065 ± 0.022 (n ¼ 10) 0.075 ± 0.013 (n ¼ 10) 0.080 ± 0.024 (n ¼ 10) 0.076 ± 0.014 (n ¼ 10) 0.078 ± 0.010 (n ¼ 10)
Female 0.075 ± 0.026 (n ¼ 10) 0.079 ± 0.012 (n ¼ 10) 0.082 ± 0.011 (n ¼ 10) 0.097 ± 0.032 (n ¼ 10) 0.089 ± 0.018 (n ¼ 10)
Testes (g) Male 0.22 ± 0.02 (n ¼ 10) 0.24 ± 0.07 (n ¼ 10) 0.24 ± 0.03 (n ¼ 10) 0.25 ± 0.06 (n ¼ 10) 0.23 ± 0.03 (n ¼ 10)
Thymus (g)
Male 0.05 ± 0.01 (n ¼ 10) 0.04 ± 0.01 (n ¼ 10) 0.04 ± 0.01 (n ¼ 10) 0.04 ± 0.01 (n ¼ 10) 0.04 ± 0.01 (n ¼ 10)
Female 0.06 ± 0.01 (n ¼ 10) 0.05 ± 0.005 (n ¼ 10) 0.05 ± 0.01 (n ¼ 10) 0.05 ± 0.02 (n ¼ 10) 0.05 ± 0.01 (n ¼ 10)
Thyroid Glands (g)
Male 0.009 ± 0.002 (n ¼ 9) 0.008 ± 0.002 (n ¼ 10) 0.008 ± 0.002 (n ¼ 10) 0.007 ± 0.002* (n ¼ 10) 0.007 ± 0.002* (n ¼ 10)
Female 0.008 ± 0.002 (n ¼ 10) 0.007 ± 0.002 (n ¼ 10) 0.007 ± 0.002 (n ¼ 8) 0.007 ± 0.001 (n ¼ 10) 0.008 ± 0.002 (n ¼ 10)
Uterus (g) Female 0.12 ± 0.06 (n ¼ 10) 0.11 ± 0.04 (n ¼ 10) 0.12 ± 0.05 (n ¼ 10) 0.12 ± 0.03 (n ¼ 10) 0.13 ± 0.04 (n ¼ 10)
Statistics: ANOVA þ Dunnett's test (Two-Sided) to compare each test group to the control group.
*P  0.05.
Table 6
Terminal body weights (g) and selective relative organ weights (%).a
Tissue Gender Vehicle control RNA negative control DvSnf7 RNA
1 mg/kg/day 10 mg/kg/day 100 mg/kg/day
Body weight (fasted) Male 28.7 ± 1.9 (n ¼ 10) 29.2 ± 2.1 (n ¼ 10) 29.8 ± 1.9 (n ¼ 10) 30.2 ± 2.0 (n ¼ 10) 29.4 ± 1.5 (n ¼ 10)
Female 24.8 ± 1.8 (n ¼ 10) 24.2 ± 1.2 (n ¼ 10) 25.2 ± 1.9 (n ¼ 10) 24.1 ± 2.1 (n ¼ 10) 24.4 ± 1.2 (n ¼ 10)
Thyroid Glands/BW Male 0.03 ± 0.00 (n ¼ 9) 0.03 ± 0.01 (n ¼ 10) 0.03 ± 0.01 (n ¼ 10) 0.02 ± 0.01* (n ¼ 10) 0.02 ± 0.01* (n ¼ 10)
Female 0.03 ± 0.01 (n ¼ 10) 0.03 ± 0.01 (n ¼ 10) 0.03 ± 0.01 (n ¼ 8) 0.03 ± 0.00 (n ¼ 10) 0.03 ± 0.01 (n ¼ 10)
Ovaries/BW Female 0.15 ± 0.04 (n ¼ 10) 0.11 ± 0.02* (n ¼ 10) 0.11 ± 0.04* (n ¼ 10) 0.11 ± 0.03* (n ¼ 10) 0.12 ± 0.02* (n ¼ 10)
Statistics: ANOVA þ Dunnett's test (Two-Sided) to compare each test group to the control group.
*P  0.05.
a Full set of relative organ weights can be found in Supplemental Table No. 1.
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addition, there were no histopathologic differences in microscopic
examination of the ovary within any of the treatment groups
(Table 7), indicating no pathological basis for the slightly lower
ovary weight compared to the vehicle control. Therefore, these
ovary weight differences were spurious and neither treatment-
related nor toxicologically relevant.3.2.7. Pathology results
There were no treatment-related gross lesions (Supplemental
Table 3) or microscopic ﬁndings (Table 7) observed in the study.
The study pathologist considered any gross or histologic changes in
individual animals to be incidental ﬁndings that were not consid-
ered test substance-related, due to a lack of relationship between
the test substance and the histologic character, prevalence, or
severity of any incidental ﬁndings. A peer review pathologist
agreed with the diagnoses of the study pathologist.4. Discussion and conclusions
Assessment of the human safety for ingested nucleic acids
should take the following into consideration: (1) the extensive
history of safe consumption of nucleic acids, including both short
and long RNA molecules with 100% sequence identity to human
transcripts, (2) “introduced nucleic acids [in biotech crops], in andof themselves, do not raise safety concerns” (U.S. FDA,1992), (3) the
extensive physiological and biochemical barriers that serve to limit
systemic exposure to, and potential for activity of, ingested nucleic
acids, and (4) empirical data demonstrating that oral exposure to
RNAwith 100% sequence identity to the consuming organism is not
associated with toxicity at exposure levels of more than a million
times higher than anticipated human exposures (Petrick et al.,
2015).
Based on the ubiquitous and broad functional nature of RNA in
all living organisms and the key functional role of the RNAi process
in plants and animals, there is a signiﬁcant history of safe con-
sumption of RNAs in the diet with a broad range of sizes, structures,
and functions (Discussed above and reviewed by (Petrick et al.,
2013, 2015)). These safely consumed sequences have been shown
to contain many RNAs with perfect sequence matches to humans
and animals (Frizzi et al., 2014; Ivashuta et al., 2009; Jensen et al.,
2013), including a subset of critical transcripts in humans
(Ivashuta et al., 2009). This safe consumption demonstrates the
robustness of a series of sequence-independent and redundant
physiological and biochemical barriers in humans and other
mammals (described above) as evidenced by the instability of RNAs
in the intestinal tract (Ballarín-Gonzalez et al., 2013), the low oral
bioavailability of oligonucleotides (Nicklin et al., 1998; Petrick et al.,
2013), and the biological fate and rapid elimination of RNAs from
the bloodstream (Christensen et al., 2013; Molitoris et al., 2009).
Table 7
Histopathology evaluation of male and female mice.
Tissue: Findings out of total examined Male Female
Vehicle
control
RNA negative
control
DvSnf7 RNA 100 mg/kg/
day
Vehicle
control
RNA negative
control
DvSnf7 RNA 100 mg/kg/
day
Adrenal Glands
Normal 9/10 10/10 10/10 9/10 8/10 6/10
Congestion, minimal 0/10 0/10 0/10 0/10 0/10 1/10
Hyperplasia, Subcapsular Cells, minimal 1/10 0/10 0/10 1/10 2/10 2/10
Hyperplasia, Subcapsular Cells, mild 0/10 0/10 0/10 0/10 0/10 1/10
Bone Marrow e Sternum
Normal 10/10 9/10 10/10 10/10 10/10 10/10
Hyperplasia 0/10 1/10 0/10 0/10 0/10 0/10
Brain
Normal 10/10 10/10 10/10 10/10 10/10 10/10
Cervix
Normal e e e 10/10 10/10 10/10
Epididymides
Normal 10/10 9/10 10/10 e e e
Debris; Cellular 0/10 1/10 0/10 e e e
Esophagus
Normal 8/8 10/10 10/10 9/10 8/8 9/10
Tissue missing 2/10 0/10 0/10 0/10 2/10 0/10
Fibrosis, minimal 0/10 0/10 0/10 1/10 0/8 0/10
Inﬂammation, subacute, submucosal,
mild
0/10 0/10 0/10 0/10 0/8 1/10
Heart
Normal 10/10 10/10 10/10 10/10 10/10 10/10
Intestine, Colon
Normal 10/10 10/10 10/10 10/10 10/10 10/10
Intestine, Duodenum
Normal 10/10 10/10 10/10 10/10 10/10 10/10
Intestine, Ileum
Normal 10/10 9/9 10/10 7/8 10/10 10/10
Tissue missing 0/10 1/10 0/10 1/10 0/10 0/10
Processing artifacts 0/10 0/10 0/10 1/10 0/10 0/10
No Microscopic correlation 0/10 0/10 0/10 1/10 0/10 0/10
Intestine, Jejunum
Normal 10/10 10/10 10/10 10/10 10/10 10/10
Kidney
Normal 7/10 6/10 9/10 8/10 9/10 8/10
Basophilia, Tubular, minimal 0/10 0/10 0/10 1/10 0/10 1/10
Cast, Tubular, minimal 2/10 0/10 1/10 e e e
Fibrosis, minimal 0/10 0/10 1/10 0/10 1/10 0/10
Hydronephrosis, minimal 1/10 1/10 0/10 e e e
Cyst, minimal 1/10 2/10 0/10 0/10 0/10 0/10
Cyst, mild 0/10 1/10 0/10 2/10 0/10 0/10
Inﬁltration, Lymphocytic 0/10 1/10 (minimal) 0/10 0/10 0/10 1/10 (mild)
Inﬂammation, acute 0/10 0/10 0/10 1/10 0/10 0/10
Liver
Normal 9/10 10/10 10/10 9/10 9/10 9/10
Necrosis, minimal 1/10 0/10 0/10 0/10 0/10 0/10
Microgranuloma, minimal 0/10 0/10 0/10 1/10 1/10 1/10
Lymph Node, Mandibular
Normal e e e
Tissue missing e e e 10/10 9/10 10/10
No Microscopic correlation e e e 0/10 1/10 0/10
Lymph Node, Mesenteric
Normal 6/7 9/9 10/10 9/10 9/10 8/9
Tissue missing 3/10 1/10 0/10 0/10 0/10 1/10
Hyperplasia, reticuloendothelial, mild 1/7 0/9 0/10 0/10 1/10 0/9
Cyst, minimal 0/10 0/10 0/10 0/10 0/10 1/9
Cyst, moderate 0/10 0/10 0/10 1/10 0/10 0/9
Nerve, Sciatic
Normal 10/10 10/10 10/10 7/7 10/10 10/10
Tissue missing 0/10 0/10 0/10 3/10 0/10 0/10
Ovaries
Normal e e e 10/10 6/10 10/10
Cyst, minimal e e e 0/10 2/10 0/10
Cyst, mild e e e 0/10 2/10 0/10
Oviducts
Normal e e e 10/10 10/10 10/10
Pancreas
Normal 10/10 10/10 10/10 10/10 10/10 10/10
Parathyroid Gland
Normal 5/5 3/3 6/6 5/5 4/4 6/6
Tissue missing 5/10 7/10 4/10 5/10 6/10 4/10
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Table 7 (continued )
Tissue: Findings out of total examined Male Female
Vehicle
control
RNA negative
control
DvSnf7 RNA 100 mg/kg/
day
Vehicle
control
RNA negative
control
DvSnf7 RNA 100 mg/kg/
day
Spinal Cord, Cervical
Normal 10/10 10/10 10/10 10/10 10/10 10/10
Spinal Cord, Lumbar
Normal 10/10 10/10 10/10 10/10 10/10 10/10
Spinal Cord, Thoracic
Normal 10/10 10/10 10/10 10/10 10/10 10/10
Spleen
Normal 9/10 10/10 9/10 10/10 9/10 10/10
Vacuolation, macrophage, minimal 0/10 0/10 1/10 0/10 0/10 0/10
Fibrosis, Capsular, minimal 1/10 0/10 0/10 0/10 0/10 0/10
Hyperplasia, White Pulp, mild 0/10 0/10 0/10 0/10 1/10 0/10
Stomach
Normal 9/10 10/10 10/10 10/10 10/10 9/10
Dilatation; mucosal; glandular, minimal 1/10 0/10 0/10 0/10 0/10 1/10
Testis
Normal 10/10 9/10 10/10 e e e
Degeneration, minimal 0/10 1/10 0/10 e e e
Thymus
Normal 9/10 10/10 10/10 10/10 9/9 10/10
Atrophy, mild 1/10 0/10 0/10 0/10 1/10 0/10
Thyroid Gland
Normal 9/9 10/10 10/10 10/10 8/9 10/10
Tissue missing 1/10 0/10 0/10 0/10 1/10 0/10
Cyst, follicular, mild 0/9 0/10 0/10 0/10 1/9 0/10
Peyer's Patch(es)
Normal 8/8 5/5 6/6 9/9 7/8 8/8
Tissue Missing 2/10 5/10 4/10 1/10 2/10 2/10
Hyperplasia, histiocytic, minimal 0/10 0/10 0/10 0/9 1/8 0/8
Uterus
Normal e e e 10/10 9/10 10/10
Dilation, minimal e e e 0/10 1/10 0/10
e Tissue not examined.
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challenge for their clinical development and necessitate develop-
ment of specialized delivery vehicles and specialized chemical
structures/modiﬁcations (Juliano, 2016). Although humans and
mammals have barriers to exogenous RNAs, it has been shown that
certain insect pests are susceptible to ingested RNAs. Therefore,
RNAi can be applied as a powerful yet extremely selective tool for
control of these susceptible insect pests in a sequence speciﬁc
manner. DvSnf7 RNA is orally active against corn rootworms when
expressed in GM maize MON 87411 and this RNA molecule has a
narrow spectrum of activity (Bachman et al., 2013).
If it is presumed that there could be a potential for biologically
meaningful uptake and potent, speciﬁc activity of ingested nucleic
acids, an assumption which requires one to ignore the scientiﬁc
literature which describes the formidable nature of the biological
barriers against exogenous RNAs, it would be logical to investigate
potential sequence complementarity of ingested RNAs. As noted
above, this complementarity is of questionable relevance given the
safe consumption of small RNAs with homology to key mammalian
transcripts (Frizzi et al., 2014; Ivashuta et al., 2009; Jensen et al.,
2013). Furthermore sequence complementarity is necessary but
insufﬁcient for predicting activity of a small RNA against a putative
gene target as target accessibility (i.e., can a target be recognized/
targeted by a RISC bound small RNA), thermodynamic criterion,
secondary structure, and other criterion can impact putative small
RNA activity if a small RNA from the diet were able to reach a target
(these criteria are reviewed by (Liu et al., 2013)). It is also important
to note that the potential impact on gene expression of any given
exogenous siRNA with a sequence match to the consuming or-
ganism (assuming uptake) is also blunted by the dilution effect of a
complex mixture of many different siRNAs (Hannus et al., 2014) aswould potentially occur following DvSnf7 RNA exposure, further
reducing the potential for suppression of “off-target genes” after
consumption.
To put into context the mammalian safety of DvSnf7 RNA
expressed in GMmaizeMON 87411, the history of safe consumption
of endogenous maize small RNAs (encoded by longer dsRNAs) with
100% identity to mammalian transcripts was documented through
an in silico bioinformatics analysis. A library of 412,769 unique
small RNA sequence reads of 21e26 nucleotides obtained from
maize grainwas used as a query to identify sequences with identity
to human (Homo sapiens), mouse (Mus musculus), and rat (Rattus
norvegicus) transcripts using the STELLAR algorithm (Kehr et al.,
2011). There were more than 500 exact sequence alignments of
21 nucleotides in length between maize small RNAs and likely
protein coding transcripts in human, mouse, and rat (Table 1). This
represents a total of 447, 2,326, and 705 unique putative target
mRNAs for endogenous maize small RNAs in humans, mouse, and
rat, respectively. These search criteria were applied because ~21 bp
sequences are produced by DICER and DICER-like nucleases and
this size facilitates the RNAi process via RISC and RISC-like com-
plexes (Hammond, 2005; Liu et al., 2009; Tomari and Zamore,
2005; Zamore et al., 2000). These results demonstrate that if bio-
informatics were applied as a hazard characterization tool for
evaluating the safety of conventional maize, the data presented
herein would thus indicate a potential hazard due to hundreds of
transcript matches with exact matches to humans and rodent
transcripts, and would call into question the safety of this widely
consumed and safe staple crop. The weight of the scientiﬁc evi-
dence therefore supports the hypothesis that bioinformatics has
limited predictive value for hazard characterization or risk assess-
ment of ingested RNAs by humans and potential non-target
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were applied to DvSnf7 RNA and there were no matches to human,
mouse, or rat transcripts, lending further support for an absence of
putative hazards due to potential exposure to sequences with exact
matches to the consuming organism from ingestion of DvSnf7 RNA
molecule.
Although the scientiﬁc literature contains a small number of
reports documenting a low level of uptake of ingested small RNAs
(speciﬁcally, micro RNAs or miRNAs) after substantial plant mate-
rial ingestion (Liang et al., 2015; Zhang et al., 2012a), the work of
Zhang and colleagues remains the only report alleging potent and
speciﬁc physiological activity of ingested RNA from plants typically
consumed as food. There is also work suggesting uptake and ac-
tivity of a plant RNA following oral exposure to honeysuckle
decoction, an aqueous extract of honeysuckle (Zhou et al., 2015). All
evaluated plant miRNAs were degraded during preparation of
honeysuckle decoction and the only remaining RNA was a single
uniquely stable RNAse resistant ribosomal RNA fragment, incor-
rectly designated as “miR2911”. This RNA sequence has ~80% GC
content and is not a miRNA (e.g. due to being a rRNA fragment, it
was removed from the miRbase miRNA database versions 20 and
21; www.mirbase.org). This sequence appears to undergo uptake
after oral gavage and was purported to have antiviral activity in
mice (Zhou et al., 2015), although these ﬁndings have not been
replicated. This stable RNA also apparently undergoes uptake in
rodents following feeding of honeysuckle (Yang et al., 2015a), but
its unique physichochemical properties and relative abundance
make this ribosomal RNA fragment unlike any typical dietary plant
small RNA (e.g. miRNA or siRNA) and therefore, studies regarding
its uptake and activity are of questionable relevance to ingestion of
small RNAs from food.
Synthetic small RNAs (miRNAs) have been cited as potential oral
RNA chemotherapeutics when evaluated in tumor prone ApcMin/þ
transgenic mice (Mlotshwa et al., 2015), work that has been cited as
supportive evidence of the dietary RNA uptake/activity hypothesis
(Yang et al., 2015b). It is important to note, however, that thesemice
have an extensive background incidence of tumors in the small
intestine and the claims of therapeutic activity (Mlotshwa et al.,
2015) are related to the number of tumors in the GI tract, a local
rather than a systemic tissue. Despite claims of a low level of ab-
sorption for one of the three tested miRNAs as evidenced by
detectionwithin intestinal RNA, these administered synthetic small
RNAs were not subjected to multiple redundant biological barriers
such as systemic nucleases and a several membrane barriers. These
barriers are known to be present as discussed above and they
present a signiﬁcant obstacle to putative systemic RNA activity
rather than the reported local activity in the intestinal tract.
Furthermore, Mlotshwa and colleagues do not provide molecular
evidence for an RNAi-mediated difference in tumor burden, calling
into questionwhether the reported ﬁndings are mediated via RNAi.
The possibility of random variability in tumor incidence was not
addressed and this study had a limited number of animals for
quantitative tumor evaluation (7 mice/group). In the present study,
there was no apparent impact on intestinal tract tissues from
DvSnf7 RNA, nor any impact on systemic tissues that would require
escape from formidable barriers and both systemic absorption and
distal tissue distribution/absorption for potential impact.
Signiﬁcant absorption and activity of ingested plant miRNAs,
antiviral activity of the ribosomal RNA fragment “miR2911”, and
oral chemotherapeutic activity of plant miRNA sequences remain
scientiﬁc ﬁndings that are inconsistent with the weight of the sci-
entiﬁc evidence regarding RNA stability and oral therapeutic po-
tential derived from decades of pharmaceutical research and this
work still awaits independent conﬁrmation and replication. In
contrast to the literature citing uptake and putative activity ofingested small RNAs, Snow and colleagues have demonstrated in
robust andwell controlled studies that the level of miRNAuptake in
mice is quite limited and more importantly, is insufﬁcient for
mediating RNAi in the ingesting organism, noting that uptake was
on the order of 100 fold lower than that needed to mediate RNAi
(Snow et al., 2013). Uptake would be 1000 to 10,000 times lower
than that needed to mediate RNAi based on the copy numbers per
cell required for initiating RNAi as reported by Title and colleagues
(Title et al., 2015). Despite several well conducted/well controlled
feeding studies challenging the concept of uptake and potential for
activity of ingested RNAs (Dickinson et al., 2013; Petrick et al., 2015;
Snow et al., 2013; Witwer et al., 2013), this concept remains an
active research area (Baier et al., 2014; Yang et al., 2015b; Zhang
et al., 2012a). However, the papers in this research area that sup-
port activity and/or uptake of ingested miRNAs seem to have in
common low copy numbers of putatively absorbed dietary RNAs
and/or potential challenges from sequencing/sample contamina-
tion (Lusk, 2014; Tosar et al., 2014; Zhang et al., 2012b), and lack
reproducibility and/or biological plausibility as evidenced by the
results of subsequent follow up studies (Auerbach et al., 2016; Bagci
and Allmer, 2016; Dickinson et al., 2013; Title et al., 2015) or the lack
of conﬁrmatory studies from other laboratories.
Based on the key biological barriers that serve to protect
mammals from exogenous RNAs, the history of safe consumption of
ingested RNAs with sequence identity to mammals, and the lack of
sequence similarity between the DvSnf7 RNA and human or rodent
transcripts, we hypothesized that there would be a virtually
nonexistent hazard potential from oral exposure to DvSnf7 RNA.
This concept was initially tested empirically in a 28 day proof of
concept toxicity study with either a pool of 21-mer siRNAs or a 218
bp dsRNA with 100% sequence identity to the mouse ortholog of
vATPase (also a rootworm-active target (Baum et al., 2007)). No
toxicity was observed at doses of 48 mg/kg per day or higher of
dsRNA with a sequence sharing 100% identity to the mouse
ortholog of vATPase (Petrick et al., 2015), indicating that dsRNAs
have a low potential for oral toxicity even when the sequence
matches the test subjects' genome/transcriptome. To further assess
this hypothesis and evaluate potential hazard in the unlikely event
of any appreciable dietary or systemic exposure to DvSnf7 RNA
from MON 87411, a study was conducted to directly test the
mammalian safety of this rootworm-active RNA sequence.
The safety of DvSnf7 RNA was evaluated by repeat oral gavage
dosing to mice over 28 days at doses of 1, 10, or 100 mg/kg body
weight per day. A repeat oral dose toxicity study was selected
because RNA is not acutely toxic and it would not be informative to
evaluate DvSnf7 RNAusing an acute toxicity study. Dose levels were
selected to ensure suitable hazard characterization and very large
margins of exposure when compared to anticipated human dietary
intake of DvSnf7 from the consumption of foods containing MON
87411. There were no treatment-related effects on survival, clinical
observations, bodyweight gain, food consumption, gross pathology
(e.g. gross examination at necropsy), or histopathology (e.g.
microscopic examination of tissues) endpoints. Therefore, the
NOAEL for DvSnf7 RNAwas considered to be 100mg/kg, the highest
dose tested.
With no identiﬁed hazard for DvSnf7 RNA, there is no antici-
pation of signiﬁcant dietary risk from consumption of this RNA
molecule when foods containing MON 87411 are consumed. Based
onmean expression of 0.000091 mg/g (ppm) freshweight of DvSnf7
RNA in grain fromMON 87411 (Urquhart et al., 2015) and mean per
capita maize consumption values in China, the EU, Japan, Korea,
Mexico, and the US, anticipated human exposure to DvSnf7 RNA
from MON 87411 is calculated to range from 8.3  107 to
2.4  104 mg/kg body weight per day (Table 8). These exposure
levels assume 100% of consumed maize is MON 87411 over an
Table 8
Estimated dietary intake and margins of exposure for DvSnf7 RNA from consumption of maize in the general population of selected geographies.
Country Mean/Capita maize consumption (g/person/day) Mean/Capita maize consumption (g/kg/day) DvSnf7 RNA intakea (mg/kg/day) Margins of exposureb
China 9.9c 0.2 1.8  105 5.6  109
European Union 9.8d 0.1 1.2  105 8.1  109
Japan 0.5e 0.009 8.3  107 1.2  1011
Korea 5.6f 0.1 9.4  106 1.1  1010
Mexico 187g 2.7 2.4  104 4.1  108
United States 115h 2.0 1.8  104 5.4  108
a Assumes 100% of maize consumed contains 0.000091 mg/g (ppm) fresh weight of DvSnf7 RNA (Urquhart et al., 2015). Unrounded consumption values used to calculate
DvSnf7 RNA intake levels.
b MOEs calculated by dividing the NOAEL from 28 day mouse gavage study (100 mg/kg DvSnf7 RNA) by DvSnf7 RNA intake. MOEs rounded to two signiﬁcant ﬁgures.
c Maize consumption is based on 2002 Chinese Nutrition and Health Survey (Zhai and Yang, 2006). An approximate body weight of 50 kg for the overall Chinese population
is an estimate based on the mean body weight of 55.9 kg for adults aged 20 through 45 (Popkin et al., 1995). Commodities included: corn products.
d Maize consumption is based on European food consumption data relevant to applications for GMOs (http://www.efsa.europa.eu/en/applications/gmo/tools); Ireland is the
highest maize consuming country based on the NSIFCS survey of adults. Maize consumption on a g/kg/day basis is derived using an average adult body weight of 73 kg for the
Irish population. Commodities included: corn bread, corn ﬂakes, corn grain, corn milling products, corn oil, corn snacks, cornmeal porridge, popcorn, and sweet corn.
e Maize consumption for the overall Japanese population is based on the Japanese National Health and Nutrition Survey conducted in 2013 (Survey located at: http://www.
mhlw.go.jp/bunya/kenkou/eiyou/h25-houkoku.html). Maize consumption on a g/kg/day basis is derived using an average body weight of 55 kg for the overall Japanese
population. Commodities included: corn e whole grain, corn e roasted and salted, popcorn and cornﬂakes.
f Maize consumption was based on 2011 Korean National Health and Nutrition Examination Survey sponsored by the Korea Health Industry Development Institute (KHIDI,
2013). Maize consumption on a g/kg/day basis is derived using aweighted average bodyweight (53.7 kg) for the general Korean population age 1 year old was obtained from
the 2005 Korean survey (KMHW, 2006). Commodities included: corn.
g Maize consumption for the general population (García-Urigüen, 2012), on a g/kg/day basis is derived using an average body weight of approximately 70 kg for the overall
adult population in Mexico. Commodities included: maize and maize-derived products.
h Corn consumption was based on Dietary Exposure Evaluation Model e Food Commodity Intake Database (DEEMFCID/Calendex version 4.02, 05-10-c, https://www.epa.
gov/pesticide-science-and-assessing-pesticide-risks/models-pesticide-risk-assessment#deem) and food consumption data from the National Health and Nutrition Exami-
nation Survey/“What We Eat in America” dietary survey for the years 2005e2010. Maize consumption on a g/kg/day user basis is derived using an average body weight of
57 kg for the overall US population. Commodities included: corn ﬂour, corn ﬂour-baby food, corn meal, corn meal-baby food, corn bran, corn starch, corn starch-baby food,
popcorn, sweet corn, and sweet corn-baby food.
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highest estimated DvSnf7 RNA exposure in humans (2.4  104 mg/
kg body weight per day, based on mean per capita consumption in
Mexico) is more than 6000 times lower than the 1.5 mg/kg/day
threshold of toxicological concern (TTC) for compounds not trig-
gering structural alerts for toxicity (Kroes et al., 2005). The TTC
concept establishes an exposure level for chemicals (with or
without toxicity data) below which there would be negligible risk
to human health from repeated exposures. Furthermore, as bio-
pesticides, the plant incorporated pesticides in MON 87411
(including DvSnf7 RNA) are generally considered to be less toxic
and to have a narrower activity spectrum (i.e. impact limited to the
target pest and closely related organisms) than conventional pes-
ticides (U.S. EPA, 2015).
To further evaluate potential risk to human consumers from
MON 87411, margins of exposurewere calculated from conservative
estimates of anticipated human exposure and the NOAEL from the
present toxicology study with DvSnf7 RNA of 100 mg/kg (Table 8)1.
Margins of exposure based on mean per capita maize consumption
values in China, the EU, Japan, Korea, Mexico, and the US ranged
from 4.1 108 to 1.2 1011. TheseMOEs would potentially be larger
if one considers the potential impact of food processing and cook-
ing that would be expected to denature and/or degrade DvSnf7 RNA
in maize-derived products obtained from MON 87411 and that the
global maize market contains/will contain many maize varieties
that do not include MON 87411. To reach a DvSnf7 dose level
equivalent to the 100 mg/kg NOAEL from the 28-day study, a hu-
man would have to eat more than 60 million kilograms of MON
87411 maize grain (DvSnf7 expression value of 0.000091 mg/g)
every day for 28 days, a physical impossibility.
The weight of the scientiﬁc evidence presented herein supports
the conclusion that DvSnf7 RNA, an effective tool for corn root-
worm control when expressed in GM maize MON 87411, is safe to
mammals after repeated dose oral exposures. The empirical1 MOE ¼ [NOAEL (mg/kg)  1000 (mg/mg)]/Protein Intake (mg/kg).scientiﬁc evidence from a repeat oral toxicity study with DvSnf7
RNA is consistent with the history of safe RNA consumption,
including sequences matching mammalian genes, and with the
extensive barriers to exogenous RNA. Even if one were to disregard
the weight of the scientiﬁc evidence and literature that calls into
question the potential for uptake and activity of ingested RNA and
presume the worst case scenario that DvSnf7 RNA undergoes sig-
niﬁcant absorption in mammals, empirical data presented herein
demonstrate that DvSnf7 RNA is not toxic to mammals at dose
levels millions to billions of times higher than conservative esti-
mates of human dietary exposure across numerous geographies.
Therefore, RNAi can be safely applied for insect control in crops
utilized for food and feed without presenting any appreciable risk
to human consumers or non-target mammals in the environment.
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